• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

R&D Status February 2017: DNDi Leishmaniasis programme

15 Feb 2017
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

DNDi aims to deliver:

  • An oral, safe, effective, low-cost and short-course treatment for visceral leishmaniasis (VL).
  • A new treatment for post-kala-azar dermal leishmaniasis (PKDL) that is shorter and better tolerated than current options.
  • A new treatment regimen for patients co-infected with HIV and VL.
  • A safe, effective, and shorter-course treatment for cutaneous leishmaniasis (CL).

DNDi’s current leishmaniasis portfolio includes:

Research

Research

Four projects in the research phase:

  • Leish H2L: This project continues to evaluate hits identified from high-throughput screens and to begin the process of optimizing these new chemical series. If promising activity can be demonstrated in in vivo models of leishmaniasis, the series will be advanced into full lead optimization. This process of ‘hit-to-lead’ optimization is ongoing with multiple series from several pharmaceutical companies.
  • DNDI-5421 & DNDI-5610 oxaboroles: These two compounds from the oxaborole class serve as back-ups to DNDI-6148. Their further development is currently put on hold and will only recommence should problems be encountered with the pre-clinical development of DNDI-6148.
  • Aminopyrazoles: The aminopyrazole class of compounds has shown promising early profiles for the treatment of both visceral and cutaneous leishmaniasis. Profiling of current and new leads in a panel of drug-sensitive and drug-resistant strains of leishmania, exploration of the in vivo dose response, rat pharmacokinetics, and initial in vitro safety assays are all underway. The ongoing lead optimization programme aims to select an optimized lead.
  • CGH VL series 1: US pharmaceutical company Celgene has been optimizing a series of quinazolines/pyridopyrimidines for VL in collaboration with the London School of Hygiene and Tropical Medicine and Advinus. An in vivo proof-of-concept has been achieved for this series. An intensive lead optimization programme is ongoing with Celgene to identify an optimized lead.

 

Translation

Translation

Four projects in the translation phase:

 DNDI-6148 oxaborole: In January 2016, DNDI-6148, from the oxaborole class, was nominated as a pre-clinical candidate for the treatment of VL. Pharmaceutical development activities (drug substance and drug product development and manufacture) have now been initiated, and the toxicity/safety pre-IND package was launched starting with dose range finding studies, along with refinement of ADME (absorption, distribution, metabolism and elimination), efficacy and safety profile to ensure a smooth transition from the pre-clinical phase to Phase I clinical phase, which should happen over the course of 2017.

  • DNDI-0690 nitroimidazole: DNDI-0690, a nitroimidazole for the treatment of VL and possibly CL, was selected for pre-clinical development in September 2015. In 2016, DNDi activities focused on pharmaceutical development activities (drug substance and drug product development and manufacture), launching of toxicity/safety pre-IND package with dose range finding studies, as well as refinement of ADME, efficacy and safety profile to ensure a smooth transition from the pre-clinical phase to Phase I clinical phase, which should happen over the course of 2017.
  • CpG-D35 for CL: This project aims to produce an immunomodulator to stimulate the innate immune system to fight the parasitic infection, as an adjunct to drug therapy. Two studies, one in vitro and one in vivo, were initiated in 2016.  The in vivo study aims to demonstrate if CpG-D35 – whether alone or in combination with antimonials chemotherapy – will lead to improved leishmania infection outcomes, compared with antimonials alone. Results are expected by mid-2017.   The in vitro study aims to assess the stimulatory capability of CpG-D35 in bothperipheral blood mononuclear cells and whole blood samples from patients with both CL, due to different leishmania species, and PKDL patients and to determine which host genes are modulated in these two conditions. Results are expected by the end of 2017.
  • New CL combination therapies: When administrated alone, the safety and efficacy profiles of current CL treatments (antimonials, miltefosine, and thermotherapy) are well established. Using a combination of therapeutic approaches may improve efficacy rates, reduce treatment duration, and improve the rate of adverse events. A combination of one single application of thermotherapy at 50°C for 30 seconds with a three-week course of oral miltefosine will be tested in order to gain information about safety and efficacy. At the end of 2016, official approvals were obtained, a site initiation visit conducted and the first patients were enrolled in Peru, while final approvals are expected by early 2017 for a second site in Colombia.

Two projects in early clinical phases were interrupted in 2016:

  • Fexinidazole/miltefosine combination: Before proceeding to a proof-of-concept study in patients, a drug-drug interaction study was to be conducted in up to 60 healthy volunteers to assess the combination’s pharmacokinetics, tolerability and safety. While ethical approval was granted, French regulatory authorities stated that there was not sufficient information available to completely rule out the fertility risk related to miltefosine exposure to justify a study in healthy volunteers. Considering the excellent activity of the new oral chemical entities currently in pre-clinical development for VL, the development of fexinidazole/miltefosine combination was therefore stopped.
  • Anfoleish for CL: The rationale for the development of a topical formulation of amphotericin B was to provide a treatment to be applied locally at the CL lesion, showing high anti-parasitic effect, but without the systemic toxicity associated with amphotericin B. A Phase Ib/II open-label, randomized, non-comparative, two-arm exploratory study was conducted in Colombia. Initially planned to include only patients with CL caused by braziliensis, recruitment was widened to include people with CL caused by L. panamensis. Enrolment of all 80 patients was completed in November 2015. Study results did not support the continuation of the clinical development of Anfoleish in its current formulation. Alternatives options are currently under consideration.

Development

Development

Four projects in the clinical development phase:

  • New treatments for HIV/VL: In 2014, a Phase III study testing both AmBisome® monotherapy (at a higher dose than current practice) and a combination of AmBisome® and miltefosine was initiated at two sites in Ethiopia for the treatment of HIV/VL co-infection. After 132 patients had been enrolled, recruitment was interrupted at the time of the second interim analysis, as efficacy at the end of treatment was lower than expected. Patients who had not achieved cure at the end of treatment were given a second cycle of the same treatment. With the extended treatment duration, results achieved with the combination treatment were found to be very promising, with the majority of patients achieving VL cure. These results were based on a limited number of patients; a new HIV/VL study is therefore under consideration to confirm the results.
  • New treatments for PKDL: A Phase II study testing both AmBisome® monotherapy and a combination of AmBisome® and miltefosine is underway in India and Bangladesh to assess the safety and efficacy for patients with post-kala-azar dermal leishmaniasis (PKDL). A separate Phase II study to assess the safety and efficacy of both AmBisome® in combination with miltefosine, and paromomycin in combination with miltefosine, is planned in Sudan. Site visits have been undertaken at all participating sites in the three countries, and protocols and study documents are under finalization for submission to ethical and regulatory review. In addition, two PKDL infectivity studies are under preparation in Bangladesh and Sudan. Their objective is to establish the infectivity of PKDL patients to sandflies, to determine if PKDL patients maintain inter-epidemic transmission of VL. If this is confirmed, early treatment of PKDL patients would be critical elements of any VL public health and elimination strategy.
  • Miltefosine/paromomycin combo for Africa: A Phase III clinical trial will be conducted in East Africa to compare the efficacy and safety of two combination regimens of miltefosine and paromomycin with the current standard VL treatment sodium stibogluconate (SSG)-paromomycin, in both paediatric and adult patients. Sites will be located in Kenya, Sudan, Uganda and Ethiopia. If the combination is proven safe and efficacious, current treatment would no longer rely on SSG, an injectable drug, which would be replaced with miltefosine, an oral drug. A safer, more field-adapted, patient-friendly treatment would particularly benefit children, who represent a high proportion of the population at risk in East Africa. The trial protocol is under finalization and will be submitted to ethics committees and regulatory authorities in early 2017.
  • New VL treatments in Latin America: In 2011, a Phase IV study sponsored by the Brazilian Ministry of Health was initiated at five sites in Brazil to evaluate the efficacy and safety of Amphotericin B deoxycholate, AmBisome® and a combination of AmBisome® and Glucantime®, in comparison to Glucantime®, the existing first-line treatment of VL. 378 patients were recruited. Brazil’s national guidelines for VL were revised in 2013 based on the interim safety data from the trial. While Glucantime® remains the first-line treatment, AmBisome® replaced Amphotericin B deoxycholate as a second-line treatment. The final results of this trial were presented to the Ministry of Health, and are expected to guide further policy change in Brazil.

Implementation

Implementation and Access

 
  • SSG&PM Africa: In East Africa, DNDi continues to support the implementation of sodium stibogluconate-paromomycin (SSG&PM), a combination VL treatment for Africa delivered in 2010 by DNDi and the Leishmaniasis East Africa Platform (LEAP). DNDi continues to support registration efforts, notably of paromomycin, and treatment availability to VL patients in the region.
  • New VL treatments Asia: In India, DNDi continues to support the rolling out of treatments as per the Indian National Kala-Azar Elimination Roadmap, after data from a DNDi implementation study contributed to a change in the national guidelines, which now recommend the use of single-dose AmBisome® in areas of high prevalence, and paromomycin/miltefosine combination in low-prevalence districts.

Photo credit: Graham Crouch-DNDi

Cutaneous leishmaniasis Visceral leishmaniasis

Read, watch, share

Loading...
Publications
16 Jun 2022

DNDi‘s Commitment to the Kigali Declaration

Statements
16 Jun 2022

DNDi written comments on the Intergovernmental Negotiating Body White Paper

Caregiver prepares 4-in-1 HIV treatment for child
Press releases
14 Jun 2022

Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa

Nurse with HIV-VL patient
Publications
8 Jun 2022

The Science Explained: Evaluating new treatment regimens for visceral leishmaniasis in people living with HIV in India and Ethiopia

Doctor with a patient
Press releases
8 Jun 2022

New WHO treatment guidelines offer hope for people co-infected with visceral leishmaniasis and HIV

Doctor talking with patient during a consultation
Press releases
1 Jun 2022

Thai partners unite with DNDi to improve access to treatments and diagnostics for people with hepatitis C in Thailand

Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

DNDi briefing document: Best science for all

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesNo description
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
_hjSessionUser_11288441 yearNo description
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo